Gilead- Short

Current Support: 69-70
Near-Term support: 63

I like Gilead for fundo reasons (massive FCF) but the market is correctly worried about declining hep c revenues and the lack of a transformative acquisition. The trend is clearly down with regards to price, MACD, and RSI. RSI trend-line needs to reverse in order for price to appreciate in my view.
biotechGILDgileadIBBshort

更多:

相关出版物

免责声明